Evidence map›Paper›PMID 21172069›Full record

ArticleAlzheimer's research & therapy2010

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials.

Joshua D Grill, Jason Karlawish

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Recruitment and Screening Methods in Alzheimer's Disease Research: The FIT-AD Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014
    Trial
  15. Trial
  16. Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013
    Trial
  17. Trial
  18. Article
  19. Engagement of understudied populations as community change: The South Texas ADRC model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  20. Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joshua D GrillMary S Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095, USA. jgrill@mednet.ucla.edu.
Jason Karlawish

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the key challenges in Alzheimer's disease drug development is the timely completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient enrollment. Successful clinical trial recruitment describes a balance between expeditiously achieving full enrollment and ensuring an appropriate study sample. Investigators face a number of challenges to the successful negotiation of this balance. The failure to address these challenges means that drug development may take more time and money and that trial results may not adequately represent drug efficacy or may not be applicable beyond the study. We review the challenges to recruitment and retention in Alzheimer's disease clinical trials and present a framework to address them.

Identifiers

PMID21172069
PMCPMC3031880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.